Atovaquone 是具有口服活性的选择性寄生虫线粒体细胞色素bc1复合物的抑制剂。它抑制人类和P. falciparum细胞色素bc1活性，IC50值分别为 460 nM 和 2.0 nM。它有抗疟作用，有潜力用于疟疾、弓形体病、肺孢子虫肺炎和巴贝斯虫病的相关研究。

Atovaquone is a hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

Atovaquone (atavaquone) is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity.[1] Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. [2]

Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), it is effective in combination with proguanil for the treatment and prevention of malaria, and it is effective in combination with azithromycin for the treatment of babesiosis. [3]

95233-18-4

C22H19ClO3

366.84

Atavaquone;阿托伐醌

DMSO:7.3 mg/mL (20 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years